KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells. [electronic resource]
Producer: 20091104Description: 63 p. digitalISSN:- 1479-5876
- Antineoplastic Agents, Phytogenic -- therapeutic use
- Apoptosis -- drug effects
- Ascites -- pathology
- Caspase 3 -- analysis
- Caspase 7 -- analysis
- Caspase 9 -- analysis
- Cell Line, Tumor
- Cell Survival -- drug effects
- Dose-Response Relationship, Drug
- Enzyme Activation -- drug effects
- Enzyme Inhibitors -- pharmacology
- Female
- Genes, Reporter
- Humans
- Inhibitory Concentration 50
- Kinesins -- antagonists & inhibitors
- Luciferases -- metabolism
- Organ Culture Techniques
- Ovarian Neoplasms -- drug therapy
- Paclitaxel -- therapeutic use
- Thiadiazoles -- antagonists & inhibitors
- Time Factors
- Transfection
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.